CPA
DAWN

Capital Performance Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Capital Performance Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-80
Closed -$1.11K – 809
2024
Q3 		$1.11K Buy
+80
New +$1.14K ﹤0.01% 1854

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Capital Performance Advisors's DAWN Position: Q4 2024 in Review

Capital Performance Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q4 2024, closing a stake of 80 shares — an estimated $1.11K sold.

Capital Performance Advisors first reported a position in DAWN in Q3 2024 and held it in 1 quarter. The position peaked at $1.11K in Q3 2024. 164 funds tracked by Wall St. Rank hold DAWN as of Q4 2024.

  • Capital Performance Advisors reported no remaining Day One Biopharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 80 Day One Biopharmaceuticals shares in Q4 2024, an estimated $1.11K.
  • Capital Performance Advisors first reported a position in Day One Biopharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Day One Biopharmaceuticals position peaked at $1.11K in Q3 2024.
  • 164 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.